Clinical Trial Title
This is a clinical trial evaluating the safety and efficacy of investigational drug for the treatment of chronic active antibody-mediated rejection in kidney transplant recipientsNational Clinical Trial Number:
NCT03744910Contact Information
Clinical Trial Protocol Description:
This is a clinical research study investigating an experimental drug vs placebo in the treatment of chronic active antibody-mediated rejection. The experimental drug is a subcutaneous injection administered every 4 weeks. Subjects are asked to come in for regularly scheduled research visits at the RUSH downtown campus.
Clinical Trial Eligibility Criteria:
In order to participate you must meet the following criteria:
- Are a living donor or deceased donor kidney transplant recipient greater than 6 months from time of transplant.
- Have a diagnosis of chronic active antibody-mediated rejection and the presence of human leukocyte antigen (HLA) DSA.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.
Study Details
Clinical Trial Investigator
Vasil Peev, MD
Contact Information
Diana Goldman
Clinical Trial Location
Rush University Medical Center